Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MAP3K5_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MAP3K5_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MAP3K5_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MAP3K5_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAP3K5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MAP3K5_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAP3K5_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAP3K5_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAP3K5_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004632812 | Lung | AIS | regulation of JNK cascade | 30/1849 | 133/18723 | 1.24e-05 | 4.75e-04 | 30 |
GO:004586012 | Lung | AIS | positive regulation of protein kinase activity | 65/1849 | 386/18723 | 1.27e-05 | 4.78e-04 | 65 |
GO:007190012 | Lung | AIS | regulation of protein serine/threonine kinase activity | 61/1849 | 359/18723 | 1.76e-05 | 6.17e-04 | 61 |
GO:006219713 | Lung | AIS | cellular response to chemical stress | 58/1849 | 337/18723 | 1.91e-05 | 6.62e-04 | 58 |
GO:003287213 | Lung | AIS | regulation of stress-activated MAPK cascade | 38/1849 | 192/18723 | 2.36e-05 | 7.81e-04 | 38 |
GO:007190211 | Lung | AIS | positive regulation of protein serine/threonine kinase activity | 38/1849 | 200/18723 | 6.00e-05 | 1.65e-03 | 38 |
GO:003459913 | Lung | AIS | cellular response to oxidative stress | 49/1849 | 288/18723 | 1.10e-04 | 2.57e-03 | 49 |
GO:007099713 | Lung | AIS | neuron death | 58/1849 | 361/18723 | 1.39e-04 | 3.05e-03 | 58 |
GO:00434101 | Lung | AIS | positive regulation of MAPK cascade | 72/1849 | 480/18723 | 2.11e-04 | 4.32e-03 | 72 |
GO:005254713 | Lung | AIS | regulation of peptidase activity | 68/1849 | 461/18723 | 5.01e-04 | 8.23e-03 | 68 |
GO:004340511 | Lung | AIS | regulation of MAP kinase activity | 32/1849 | 177/18723 | 5.53e-04 | 8.71e-03 | 32 |
GO:003166813 | Lung | AIS | cellular response to extracellular stimulus | 41/1849 | 246/18723 | 5.90e-04 | 9.03e-03 | 41 |
GO:190121413 | Lung | AIS | regulation of neuron death | 50/1849 | 319/18723 | 6.90e-04 | 1.02e-02 | 50 |
GO:003497613 | Lung | AIS | response to endoplasmic reticulum stress | 42/1849 | 256/18723 | 7.09e-04 | 1.04e-02 | 42 |
GO:003806611 | Lung | AIS | p38MAPK cascade | 14/1849 | 55/18723 | 7.09e-04 | 1.04e-02 | 14 |
GO:007149613 | Lung | AIS | cellular response to external stimulus | 50/1849 | 320/18723 | 7.41e-04 | 1.07e-02 | 50 |
GO:003647313 | Lung | AIS | cell death in response to oxidative stress | 20/1849 | 95/18723 | 8.52e-04 | 1.17e-02 | 20 |
GO:001095213 | Lung | AIS | positive regulation of peptidase activity | 34/1849 | 197/18723 | 8.94e-04 | 1.20e-02 | 34 |
GO:007005913 | Lung | AIS | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 15/1849 | 63/18723 | 9.87e-04 | 1.29e-02 | 15 |
GO:005254813 | Lung | AIS | regulation of endopeptidase activity | 63/1849 | 432/18723 | 1.06e-03 | 1.38e-02 | 63 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0501220 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa0501018 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
hsa0501618 | Cervix | CC | Huntington disease | 94/1267 | 306/8465 | 8.49e-13 | 3.06e-11 | 1.81e-11 | 94 |
hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa0493218 | Cervix | CC | Non-alcoholic fatty liver disease | 58/1267 | 155/8465 | 3.58e-12 | 1.05e-10 | 6.23e-11 | 58 |
hsa0471420 | Cervix | CC | Thermogenesis | 76/1267 | 232/8465 | 4.29e-12 | 1.16e-10 | 6.85e-11 | 76 |
hsa0501418 | Cervix | CC | Amyotrophic lateral sclerosis | 103/1267 | 364/8465 | 1.79e-11 | 4.47e-10 | 2.64e-10 | 103 |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0414120 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa0453020 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0407110 | Cervix | CC | Sphingolipid signaling pathway | 35/1267 | 121/8465 | 5.70e-05 | 3.93e-04 | 2.32e-04 | 35 |
hsa042109 | Cervix | CC | Apoptosis | 36/1267 | 136/8465 | 3.21e-04 | 1.68e-03 | 9.91e-04 | 36 |
hsa0472214 | Cervix | CC | Neurotrophin signaling pathway | 32/1267 | 119/8465 | 5.01e-04 | 2.42e-03 | 1.43e-03 | 32 |
hsa0501716 | Cervix | CC | Spinocerebellar ataxia | 35/1267 | 143/8465 | 1.77e-03 | 7.21e-03 | 4.26e-03 | 35 |
hsa046686 | Cervix | CC | TNF signaling pathway | 28/1267 | 114/8465 | 4.60e-03 | 1.62e-02 | 9.59e-03 | 28 |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa05208110 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa05012110 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP3K5 | SNV | Missense_Mutation | rs771379166 | c.3427C>T | p.Arg1143Trp | p.R1143W | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAP3K5 | SNV | Missense_Mutation | | c.1276N>A | p.Glu426Lys | p.E426K | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AC-A2B8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | chemo | PD |
MAP3K5 | SNV | Missense_Mutation | | c.3040C>T | p.Arg1014Trp | p.R1014W | Q99683 | protein_coding | deleterious(0.02) | probably_damaging(0.993) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP3K5 | SNV | Missense_Mutation | | c.702N>C | p.Leu234Phe | p.L234F | Q99683 | protein_coding | tolerated(0.08) | possibly_damaging(0.883) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP3K5 | SNV | Missense_Mutation | novel | c.1307N>A | p.Ala436Glu | p.A436E | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0FZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAP3K5 | SNV | Missense_Mutation | novel | c.1531N>T | p.Leu511Phe | p.L511F | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0B7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
MAP3K5 | SNV | Missense_Mutation | novel | c.2311N>A | p.Gly771Ser | p.G771S | Q99683 | protein_coding | deleterious(0) | possibly_damaging(0.896) | TCGA-BH-A0BL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
MAP3K5 | SNV | Missense_Mutation | | c.1276G>A | p.Glu426Lys | p.E426K | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
MAP3K5 | SNV | Missense_Mutation | novel | c.3817G>A | p.Ala1273Thr | p.A1273T | Q99683 | protein_coding | tolerated(0.79) | benign(0.257) | TCGA-E2-A14R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
MAP3K5 | SNV | Missense_Mutation | novel | c.850C>G | p.Arg284Gly | p.R284G | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | | GS-4997 | SELONSERTIB | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 249565756 | | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | | GS-4977 | | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 249565813 | | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 385612190 | | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | CHEMBL3545429 | SELONSERTIB | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | | hydroxyurea | HYDROXYUREA | 23556445 |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 315661125 | SELONSERTIB | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 404859049 | | |